Anaptysbio (ANAB) Change in Receivables (2016 - 2017)

Anaptysbio (ANAB) reported Change in Receivables of -$1.2 million for Q1 2017, down 3400.0% on a YoY basis from $37121.2 in Q1 2016, and down 435.62% quarter-over-quarter from $365000.0 in Q4 2016.

Anaptysbio (ANAB) Change in Receivables (2016 - 2017) Analysis & Trends

Anaptysbio has reported Change in Receivables for 2 years, with the latest figure at -$1.2 million in Q1 2017.

  • For the quarter ending Q1 2017, Change in Receivables fell 3400.0% year-over-year to -$1.2 million; the trailing twelve-month figure through Dec 2017 stood at -$1.2 million (down 122400.0% YoY), and the FY2017 full-year result was -$1.2 million, down 122400.0% from the prior year.
  • Change in Receivables for Q1 2017 stood at -$1.2 million, down from $365000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $365000.0 in Q4 2016, with the low at -$1.2 million in Q1 2017.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 22,529.00
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -39.80 Mn
9 Abivax 91.96 Bn 91.96 Bn - -4.08 Mn
10 Anaptysbio 1.66 Bn 1.38 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2017 -1.23 Mn
Mar 31, 2017 -1.23 Mn
Dec 31, 2016 365,000.00
Dec 31, 2016 365,000.00
Sep 30, 2016 -120,000.00
Sep 30, 2016 -120,000.00
Jun 30, 2016 -211,000.00
Jun 30, 2016 -211,000.00
Mar 31, 2016 -35,000.00
Mar 31, 2016 -35,000.00